Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPEG-IFN alpha-2a Plus Ribavirin in Untreated Chronic Hepatitis C
NCT01327729Phase 3Unknown
- Sponsor
- BioGeneric Pharma
- Start
- Nov 2010
- Primary completion
- Apr 2011
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of ypeg-interferon alpha-2a in hepatitis C (HCV), sponsored by BioGeneric Pharma. Status: unknown.
02
Drugs
ypeg-interferon alpha-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01327729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01327729.